Dendreon shares slump as demand for Provenge disappoints
This article was originally published in Scrip
Dendreon has been forced to withdraw its sales estimates for 2011, claiming the uptake of its therapeutic prostate cancer vaccine Provenge (sipuleucel-T) is being hampered by confusion over reimbursement. That official company line has been countered by others who say that demand for the treatment per se rather than any confusion is at the root cause of the sale deficit. Dendreon’s share price dived by more than 60% on extended trading on 3 August following the announcement.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.